ASH Data Offer Treatment Direction for Oncology Nursing Professionals


Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.

In this episode of The Vitals, Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss data from the 64th American Society of Hematology Annual Meeting and Exposition that have the greatest potential to change oncology nursing practice.

Kalariya, a nurse practitioner with the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, recently spoke with Oncology Nursing News® highlighted research from the University of Pennsylvania which showed clinical utility of a frailty phenotype tool and contextualized the role of CAR T-cell therapy for patients with multiple myeloma. He also discussed whether data from a subgroup analysis of patients with multiple myeloma who received the anti-BCMA CAR T-cell therapy in the KarMMa-2 trial (NCT03601078) supports moving it forward in the treatment lineup.

Zitella, a nurse practitioner in the Department of Hematology, Blood & Marrow Transplant, and Cellular Therapies Program at the UCSF Helen Diller Family Comprehensive Cancer Center and an associate clinical professor with the School of Nursing University of California, San Francisco, also spoke with Oncology Nursing News®, highlighting exciting advances with BTK inhibitors and how nurses can promote safe eating habits after data from ASH demonstrated that the neutropenic diet does not benefit patients. on which data from the 2022 ASH meeting might have the greatest impact on nurses working in hematologic oncology.

Interested in learning more from ASH? Check out our coverage of the 2022 ASH Meeting here.

We want to hear from you! Which ASH data do you think will be practice-changing? Email with your feedback.

Episode Notes:

“This study that came out at ASH in a transplant population, which is the most immunocompromised population really highlights the [neutropenic diet] and brings it front and center. Hopefully, this will be enough to convince people to abandon the neutropenic diet.” Time stamp (TS) 3:25

“What we see here is that CAR T-cell therapy, followed by maintenance therapy might be a key in frontline settings to have a longer duration of response.” TS 8:30.

“For relapsed or refractory chronic lymphocytic leukemia, zanubrutinib [Brukinsa] had a better overall response rate and progression-free survival than ibrutinib [Imbruvica].” TS 10:19

The Vitals Podcast:

Stephanie Jackson Unpacks Recent Advances in Leukemia Treatments

Cardiac Complications in Blood Cancers

Oncology Nursing News® Online Articles

Video Interviews

Aaron Gerds on JAK Inhibitor Therapy for Anemic Patients With Myelofibrosis


  1. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26(35):5684-5688. doi:10.1200/JCO.2008.16.4681
  2. Usmani S, Patel K, Hari P, et al. KarMMa-2 cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Blood. 2022;140(suppl 1):875-877. doi:10.1182/blood-2022-162469
  3. Dhodapkar M, Alsina M, Berdeja J, et al. KarMMa-2 cohort 2c: efficacy and safety of idecabtagene vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation. Blood. 2022;140 (suppl 1):7441–7443. doi:10.1182/blood-2022-162615
  4. Stella F, Marasco V, Levati GV, et al. Non-restrictive diet does not increase infections in patients with neutropenia after stem cell transplantation: final analysis of the Neutrodiet multicenter, randomized trial. Presented at ASH 2022. December 10-13, 2022. Abstract 169.
  5. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. Published online December 13, 2022. doi:10.1056/NEJMoa2211582
  6. Mato AR, Woyach, JA, Brown, JR, et al. Efficacy of pirtobrutinib in covalent BTK-Inhibitor pre-treated relapsed / refractory CLL/SLL: additional patients and extended follow-up from the phase 1/2 BRUIN study. Blood. 2022;140(suppl 1):2316-2360.
  7. Dreyling M, Doorduijn, JK,Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022;140(suppl 1):1-3.

Related Videos
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, in an interview with Oncology Nursing News
Andrea Wagner, M.S.N., RN, OCN, in an interview with Oncology Nursing News discussing her abstract on verbal orders for CRS.
John Rodriguez in an interview with Oncology Nursing News discussing his abstract on reducing nurse burnout
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.